• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Harvoni Shows Success Against Uncommon HCV Variants

Article

A treatment approved for the most common form of hepatitis C in the US was also highly effective in less widespread variants, researchers reported at the European Association for the Study of the Liver annual meeting.

A treatment approved for the most common form of hepatitis C (HCV) in the US was also highly effective in less widespread variants, researchers reported.

The 2-drug single-pill combination of sofosbuvir and ledipasvir (Harvoni) is indicated in the U.S. for genotype 1 HCV infection, noted Armand Abergel, MD, PhD, of the Hopital d'Estaing in Clermont-Ferrand, France, and colleagues.

But in an open-label study among patients with genotypes 4 and 5 disease, the combination yielded efficacy results that were similar to those seen in genotype 1, Dr Abergel reported in a plenary session at the European Association for the Study of the Liver annual meeting.

Read more at MedPage Today: http://bit.ly/1b6xuWA

Related Videos
Video 1 - "NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer"
Camilla Levister
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Video 12 - "Key Considerations for Treating Patients Diagnosed With CLL and SLL"
Video 11 - "Optimizing BTKi Treatment Strategies"
Video 13 - "Other Clinical Considerations in Demodex Blepharitis Treatment"
Video 12 - "Cost-Effective Medication Access in Demodex Blepharitis Management"
Video 10 - "Patient Education Drives BTK Inhibitor Treatment Adherence"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.